Unfolding like 100 years of home video footage that were shot by the family ghosts, Mascha Schilinski’s rich and mesmeric “ ...

Deep dive into RBAC vs ReBAC for enterprise sso. Learn which authorization model fits your ciam strategy and how to avoid role explosion in complex apps.

AI chipmaker Nvidia (NVDA) and pharmaceutical giant Eli Lilly (LLY) on Monday announced that the two companies would jointly invest $1 billion to create a lab in San Francisco focused on using AI to ...

Cosmologists are increasingly entertaining a radical possibility: that the cosmos might fold back on itself so that, on the ...

The Admiral Twin Drive-In in Tulsa stands as a magnificent time capsule where cinema magic meets starlit Oklahoma skies, creating an experience that will have you wondering why you waited so long to ...

The Admiral Twin Drive-In in Tulsa stands as a magnificent time capsule where cinema magic meets starlit Oklahoma skies, drawing movie lovers from Broken Arrow to Bartlesville and beyond. Remember ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...